Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | CCR3 | P51677 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196799 | 0.92 | CCR3 (0.50) | HTTCCR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4195012 | 0.90 | SMN1; SMN2 (0.47) | HTTCCR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4202574 | 0.89 | RAB9A (0.46) | HTTCCR3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4191213 | 0.88 | CCR3 (0.55) | CCR3NPC1RAB9ASMN1; SMN2KLK7 | |
| SCHEMBL4184490 | 0.87 | MEN1 (0.47) | HTTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4193519 | 0.87 | MEN1 (0.47) | HTTNPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4186045 | 0.85 | MEN1 (0.48) | HTTSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4185847 | 0.85 | KMT2A (0.47) | NPC1RAB9ASMN1; SMN2POLBEPHX1 | |
| SCHEMBL4197445 | 0.85 | KMT2A (0.48) | HTTCCR3SMN1; SMN2POLBKMT2A | |
| SCHEMBL4196629 | 0.85 | KMT2A (0.48) | HTTCCR3SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | claimed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | claimed |
| EP-1879877-B1 | ANTIMICROBIAL AGENTS | RANBAXY LAB LTD (IN) | 2013-01-02 | — | — | EP | disclosed |
| US-8076370-B2 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20090215764-A1 | Antimicrobial agents | RANBAXY LABORATORIES LIMITED (IN) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215764-A1 | Antimicrobial agents | TUFM, RPS17, HARS1 | HTT 390/4885CCR3 3584/4885NPC1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.